Fractalkine receptor has been demonstrated to be expressed in several cancer types (e.g., prostate, pancreas, breast carcinoma, glioma, and neuroblastoma), and this pathway has been demonstrated to play a role in tumorgenesis and metastasis [72]. This evidence concerns the gene CX3CR1 and neuroblastoma.